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Abstract
Hepatitis B virus (HBV) infection and its sequelae remain a major public health burden, but
both HBV basic research and the development of antiviral therapeutics have been hindered
by the lack of an efficient in vitro infection system. Recently, sodium taurocholate cotrans-
porting polypeptide (NTCP) has been identified as the HBV receptor. We herein report that
we established a NTCP-complemented HepG2 cell line (HepG2-NTCP12) that supports
HBV infection, albeit at a low infectivity level following the reported infection procedures. In
our attempts to optimize the infection conditions, we found that the centrifugation of HepG2-
NTCP12 cells during HBV inoculation (termed “spinoculation”) significantly enhanced the
virus infectivity. Moreover, the infection level gradually increased with accelerated speed of
spinoculation up to 1,000g tested. However, the enhancement of HBV infection was not sig-
nificantly dependent upon the duration of centrifugation. Furthermore, covalently closed cir-
cular (ccc) DNA was detected in infected cells under optimized infection condition by
conventional Southern blot, suggesting a successful establishment of HBV infection after
spinoculation. Finally, the parental HepG2 cells remained uninfected under HBV spinocula-
tion, and HBV entry inhibitors targeting NTCP blocked HBV infection when cells were spino-
culated, suggesting the authentic virus entry mechanism is unaltered under centrifugal
inoculation. Our data suggest that spinoculation could serve as a standard protocol for en-
hancing the efficiency of HBV infection in vitro.
Introduction
Hepatitis B virus (HBV) is a hepatotropic enveloped DNA virus that causes transient and
chronic hepatitis B in humans [1]. HBV mainly infects hepatocytes and establishes a pool of a
nuclear episomal covalently closed circular (ccc) DNA form of the viral genome, which serves
as transcription template for all the viral RNAs, including 3.5kb precore mRNA and prege-
nomic (pg) RNA, 2.4kb and 2.1kb surface protein mRNAs, and 0.7kb X mRNA. The DNA
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replication of HBV is catalyzed by viral DNA polymerase in cytoplasmic viral capsid through
reverse transcription of the HBV pgRNA precursor, and subsequently the mature double
stranded DNA-containing nucleocapsid is enveloped by viral surface glycoproteins and secret-
ed as progeny virion [1, 2].
HBV has infected approximately 2 billion people worldwide, resulting in 350–400 million
chronic infections; this significant epidemic level of hepatitis B is partly due to the high infec-
tivity of HBV in vivo when the prophylactic vaccination is not in place [3]. It has been reported
that the inoculation of a single HBV infectious particle in chimpanzee was able to establish an
acute HBV infection in 100% of the hepatocytes [4]. Ironically, a robust HBV in vitro infection
has been difficult to achieve in the hepatocyte-derived cells, which is, presumably, due to the
loss of HBV receptor(s) in the transformed or cancerous hepatocytes, or the destruction of in
vivo architecture and/or environment of hepatocytes when the cells are plated into monolayer
on petri dish. Although primary human hepatocytes (PHHs) and the HepaRG cell line can be
used for certain HBV infection experiments, the PHHs are costly with limited supply, and their
genetic background and susceptibility to HBV infection vary from donor to donor [5]; in these
regards, the HepaRG system does have advantages over PHH but time-consuming cell prolifer-
ation and differentiation steps are required prior to infection [6]. What’s more, the HBV infec-
tivity in these two cell systems remains extremely inefficient. Thus, the basic and antiviral
research of HBV in the context of a complete viral life cycle have been hampered for a long pe-
riod of time. Recently, the Na+-taurocholate cotransporting polypeptide (NTCP) has been
identified as a functional HBV receptor, creating a paradigm-shifting platform for HBV re-
search [7]. Now, the reconstitution of NTCP expression in commonly used hepatocyte-derived
cells (i.e. HepG2 and Huh7) confers permissiveness of cells to HBV infection, fostering novel
mechanistic and therapeutic studies on the early steps of the HBV life cycle, including recep-
tor-mediated HBV entry, uncoating, and first round cccDNA formation, etc. Nevertheless, the
reported HBV infectivity of NTCP-expressing cells varies among different laboratories under
different infection conditions, but the average percentage of HBcAg or HBsAg positive cells re-
mains low as revealed by immunofluorescence [7–11]. Therefore, further optimization and
standardization of the protocol for HBV infection in NTCP-expressing cells is warranted.
Spinoculation, also known as centrifugal inoculation, has been widely used to augment the
in vitro infectivity of a variety of viruses in adhesion and suspension cultures since its first ap-
plication in virus infection in 1960’s [12, 13]. Various mechanisms for this enhancement have
been proposed, from ultrastructural changes in the host cell that render it more permissive to
viruses [14], to (surprisingly for such low centrifugation speeds) increased deposition of virions
on the cell surface [15]. Herein, we established a HepG2-based NTCP-expressing cell line
which is permissive to HBV infection, and developed a spinoculation method to enhance HBV
infection with the optimized cell culture conditions and viral inoculum size. In addition, the
enhanced HBV infection by spinoculation is in an NTCP-dependent manner, suggesting that
spinoculation promotes HBV infection through the authentic viral entry mechanism. There-
fore, spinoculation could serve as a routine procedure in the protocol of in vitroHBV infection.
Materials and Methods
Plasmids and drugs
Plasmid pcDNA6-NTCP that expresses the rhodopsin C9-tagged human NTCP and the blasti-
cidin resistance gene in mammalian cells was kindly provided by Dr. Wenhui Li (National In-
stitute of Biological Sciences, Beijing, China) [7]. The 1.3-mer HBV plasmid pHBV1.3 has been
described previously and was further modified to remove an additional polyadenylation signal
in the vector sequence downstream of the HBV genome, by which prevents the synthesis of
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overlength HBV mRNAs with 3’ non-HBV sequence [16]. HBV entry inhibitor Myrcludex-B
is a gift from Dr. Stephan Urban (University Hospital Heidelberg, Heidelberg, Germany) [9].
Cyclosporin A and Sodium taurocholate were purchased from Sigma-Aldrich (St. Louis, MO).
Establishment of cell line that stably expresses NTCP
The HepG2 cells (Clone N6, a gift from Dr. David Anderson (Burnet Institute, Melbourne, Aus-
tralia)) were maintained in Dulbecco’s modified Eagle’s medium (DMEM)-F12 medium (Media-
tech, Manassas, VA) supplemented with 10% fetal bovine serum, 100 IU/ml penicillin and
100 μg/ml streptomycin. No endogenous NTCP was detected in HepG2 cells [7, 9] (data not
shown). To reconstitute NTCP expression, HepG2 cells were transfected with plasmid
pcDNA6-NTCP by Lipofectamine 2000 (Life Technologies) for 48 h, then the transfected cells
were split (1:24) and selected with 8 μg/ml blasticidin. Twenty four blasticidin-resistant colonies
were picked and expanded into cell lines. The expression level of NTCP in the candidate cell
clones were measured byWestern blot with antibody against C9-epitope (Santa Cruz Biotechnol-
ogy, cat#: SC-57432). One cell line that supported high levels of NTCP expression and HBV in-
fection was designated as HepG2-NTCP12 and was used in this study. HepG2-NTCP12 cell line
was maintained in the same way as HepG2 cells except for the addition of blasticidin (8 μg/ml).
Preparation of HBV inoculum
HBV particles were collected from the supernatant of HepDE19 cells as described previously
with modifications [17]. Briefly, HepDE19 cells were cultured in tetracycline-free medium to
induce HBV replication and virion production, supernatant was collected every other day with
culture medium replenishment for 18 days. The pooled supernatant was mixed with polyethyl-
ene glycol (PEG)-8000 powder (final concentration of 10%) and gently rotated at 4°C for over-
night, HBV particles were then precipitated by centrifugation at 1,000×g for 30 min at 4°C and
re-dissolved in serum-free DMEM/F12 medium with 1% volume of the original supernatant
samples. The concentrated virus stocks were aliquoted and stored at -80°C.
HBV particle gel assay and viral RNA/DNA analysis
HBV particle gel assay was performed as previously described [17]. Briefly, the viral particles in
the PEG-concentrated HBV inoculum were fractionated by electrophoresis (22 V, 16 h)
through nondenaturing 1% agarose gel and capillarilly transferred onto the nitrocellulose filter
(Whatman). The DNA-containing viral particles on the membrane were first denatured in a
solution containing 0.5 M NaOH and 1.5 M NaCl and then neutralized by 1 M Tris-HCl (pH
7.4) and 1.5 M NaCl, followed by UV crosslink. HBV DNA was detected by hybridization with
a [α-32P] UTP (800 Ci/mmol; Perkin Elmer)-labeled minus-strand-specific full-length
HBV riboprobe.
Intracellular HBV RNA Northern blot analysis, extracellular and intracellular HBV core
DNA and cccDNA Southern blot analysis, were performed according to our previous publica-
tions [16, 18–20]. The probe used in Northern blot is an [α-32P] UTP (800Ci/mmol; Perkin
Elmer)-labeled plus-strand-specific full-length HBV riboprobe.
The quantification of HBV total DNA was done by using Faststart Essential DNA Probes
Master (Roche). The primer and probe sequences used in real-time PCR reaction were: forward
primer: 5’-CCGTCTGTGCCTTCTCATCTG-3’, reverse primer: 5’-AGTCCAAGAGTYCTCT
TATGYAAGACCTT-3’, and probe: 5’-FAM-CCGTGTGCACTTCGCTTCACCTCTGC-TAM
RA-3’. The amplification setting was 0.8 μM of primers and 0.2 μM probe, annealing and ex-
tension at 64°C for 45 cycles.
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HBV Infection and spinoculation
HepG2-NTCP12 cells were seeded into collagen-coated 24-well plates with density of 2×105
cells/well and cultured in regular DMEM/F12 medium for overnight, and then the culture medi-
um was switched to primary hepatocytes maintenance medium (PMM), specifically Williams E
medium supplemented with 10% FBS, 5 μg/ml transferrin, 10 ng/ml hEGF, 3 μg/ml insulin, 2
mM L-glutamine, 18 μg/ml hydrocortisone, 40 ng/ml dexamethasone, 5 ng/ml sodium selenite,
2% dimethyl sulfoxide (DMSO, cell culture grade), 100 U/ml penicillin, and 100 μg/ml strepto-
mycin [7]. After 24 h, the cells were incubated with HBV inoculum diluted in PMM containing
4% PEG-8000. To perform spinoculation, the HBV inoculated plate was immediately centrifuged
at room temperature with specified speed and time. The cells received regular HBV inoculation
or spinoculation were transferred to 37°C CO2 incubator. 18 h later, the HBV inocula were re-
moved and the infected cells were maintained in regular PMMwithout PEG before harvest.
Western blot
Cells in one well of a 24-well plate were lysed in 100 μl of 1× Laemmli buffer and denatured at
95°C for 10min. 25 μl of the cell lysate was resolved in a 12% SDS-PAGE gel, and proteins were
transferred onto an Immobilon PVDF-FL membrane (Millipore). The membranes were
blocked with WesternBreeze Blocker and probed with antibodies against C9-tag (Santa Cruz
Biotechnology, cat#: SC-57432) and β-actin (Millipore, cat# MAB1501). Bound antibodies
were revealed by IRDye secondary antibodies and visualized using the LI-COR Odyssey
system.
Immunofluorescence assay
Cells were fixed with 4% paraformaldehyde for 20 min and permeabilized by 0.5% Triton X-
100 in PBS for 60 min at room temperature. Cells were subsequently blocked with 10% FBS
plus 2% BSA for 60 min at room temperature, and then incubated with anti-C9 tag antibody or
anti-HBcAg (Dako, cat#: B0586) diluted in PBS containing 10% FBS and 2% BSA for 2 h at
room temperature. After being washed with PBS, the cells were stained with Alexa Fluor 594
dye-conjugated secondary antibody (Life Technologies) and the nuclei were counterstained
with DAPI for 60 min at room temperature. Finally, the cells were washed with PBS and then
subjected to Nikon Eclipse TE 2000-U fluorescent microscopy or Olympus FV1000 MPE con-
focal microscopy analysis with the 60× objective. Images were analyzed using the FV10-ASW
3.0 Viewer Software.
Results
Establishment of NTCP-reconstituted HepG2 cells
Based on the previously published literature [7], we transfected HepG2 cells with plasmid
pcDNA6-NTCP which expresses the rhodopsin C9-tagged human NTCP and the blasticidin
resistance gene, and obtained 16 antibiotic-resistant, NTCP-expressing cell lines. Among them,
one cell line that expressed the highest level of NTCP was designated as HepG2-NTCP12 and
used in subsequent studies. As shown in Fig 1, the expression of C9-tagged NTCP in
HepG2-NTCP12 cells, but not in the parental HepG2 cells, was confirmed by both Western
blot and immunofluorescence microscopy analyses. Microscopic imaging demonstrated a
marked pattern of cell surface expression of NTCP in HepG2-NTCP12 cells, which is consis-
tent with the localization of endogenous NTCP in hepatocytes [21]. In addition, transfection of
plasmid pHBV1.3 into HepG2-NTCP12 cells resulted in HBV RNA transcription and core
DNA replication (data not shown), indicating that HepG2-NTCP12 cell line is capable of
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supporting HBV replication in viral infection, if the early entry steps up to cccDNA formation
could be fulfilled.
Determination of virion genome equivalent in the HBV inoculum
The HBV inoculum was prepared by 100-fold concentration of the virus-containing superna-
tant from HepDE19 cells with PEG as described previously [6]. It is known that the HBV pro-
ducing cells secrete enveloped virions and a considerable amount of nonenveloped “naked”
capsids in vitro, both contain viral DNA, but only virions being infectious [17, 20, 22, 23]. Fur-
thermore, while HBV virion contains double stranded DNA genome only, the naked capsids
contain heterogeneous core DNA replicative intermediates (Cai and Guo, unpublished data).
In order to calculate the virion genome equivalent (vge) of the HBV inoculum more accurately,
we developed a method to serve this purpose. First, native particle gel assay was performed to
determine the ratio between HBV virion DNA and naked capsid DNA in the HBV stock (Fig
2A), then the total amount of particle-associated HBV DNA was quantified by Southern blot
hybridization using an HBV double stranded linear DNA with known copy number as stan-
dard (Fig 2B). Alternatively, total HBV DNA was quantitated by qPCR (data not shown). Fi-
nally, the vge of HBV inoculum was calculated by normalizing the HBV DNA copy number
with the percentage of virion DNA among total viral DNA from HBV particles (Fig 2C). By
using the above virus titration method, the vge of the HBV inoculum we prepared from
HepDE19 cells is approximately 7.6×107 virions/μl.
Effects of DMSO and inoculum size on HBV infection
Next, we tested the susceptibility of HepG2-NTCP12 cells to HBV infection. As shown in Fig 3,
inoculation of HepG2-NTCP12 cells by HBV at 100 vge/cell exhibited HBcAg immunofluores-
cent signals in a small percentage of cells at day 8 post infection, but the percentage of HBcAg
positive cells was increased by 3 fold to above 10% when the infection was performed in the
Fig 1. NTCP expression in HepG2-NTCP12 cells. The stable expression of C9-tagged NTCP in HepG2-NTCP12 cells were detected byWestern blot (A)
and immunofluorescence microscopy (B) using antibody against C9 epitope. The parental HepG2 cells served as negative control.
doi:10.1371/journal.pone.0129889.g001
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presence of 2% DMSO in the culture medium (Fig 3A). HBV RNAs were detected in the in-
fected cells by Northern blot, indicating successful mRNA transcription from the established
cccDNA during infection. Similar to the enhanced HBcAg expression by DMSO, the compound
also increased the steady state levels of HBV RNA in the infected cells (Fig 3B). DMSO has been
used as a differentiation inducer for HepaRG cells to become susceptible to HBV infection,
partly through upregulating hepatocyte-specific host factors including NTCP and certain he-
patic transcription factors required for HBV entry and cccDNA transcription [6, 24]. Consis-
tent with our result, DMSO was also found to enhance HBV infection in NTCP-reconstituted
HepG2 and Huh7 cells [9]. Therefore, DMSO was routinely included in the PMM infection me-
dium in following studies. However, viral DNA replicative intermediates were only detected by
qPCR, but not by conventional Southern blot (data not shown), indicating that the level of
HBV infection and/or replication remained low under this infection condition.
One possible reason for the observed low infection level was the low percentage of infectious
virion in the prepared HBV inoculum from cell cultures. We then performed HBV infection
with different inoculum size. As shown in Fig 4, HBcAg-positive cell number and the steady
state level of HBV RNA gradually raised with the increase of HBV vge per cell, and the viral
Fig 2. Quantification of the genome equivalent of HBV virion DNA in concentrated HBV particles. (A)
HBV virions and naked capsids in the indicated volume of virus stock were separated by native agarose gel
electrophoresis, and viral DNA was detected by hybridization. The virion DNA to capsid DNA ratio was
calculated by ImageQuant IQTL software using the hybridization signal intensity. (B) HBV DNA were
extracted from 10 μl of virus stock and subjected to Southern blot analysis, 100 pg of 3.2 kb HBV linear DNA
(approximately 3.1×107 HBV DNA copies quantified by qPCR) served as loading marker. HBV DNA
replicative intermediates, including relaxed circular (RC) DNA and single stranded (SS) DNA were labeled.
The copy number of total HBV DNA was quantified by using the HBV DNA loading marker as standard. (C)
Formula for calculation of HBV virion DNA genome equivalent (v.g.e).
doi:10.1371/journal.pone.0129889.g002
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core DNA became detectable by Southern blot when more than 300 vge/cell was used. There was
a slight increase of HBV reproduction when compared 500 vge/cell to 300 vge/cell. Based on
those observations, we chose 500 vge/cell as standard inoculum in the following experiments.
Enhancement of HBV infection by spinoculation
Spinoculation has been widely used to augment the infection of many different viruses, but it
has not been applied in HBV infection thus far. In order to achieve a better HBV infection in
HepG2-NTCP12 cells, we performed HBV infection through centrifugal inoculation. Intrigu-
ingly, HBV infection was significantly enhanced by spinoculation and positively correlated to
the centrifugal force (up to 1,000g tested), as demonstrated by HBcAg immunofluorescence,
HBV RNA and DNA hybridization. Spinoculation at 1,000g for 30 min enhanced HBV infec-
tion by more than two fold versus regular infection (Fig 5). No cytotoxicity or drastic cell mor-
phological alteration was observed during the entire infection, except that the cells became
noticeably flatter after centrifugation and then gradually recovered to normal morphology in
the following culture period (data not shown).
We next assessed the effect of centrifugation time on HBV spinoculation. As shown in Fig
6A and 6B, with a fixed centrifugal force at 1,000g, extending centrifugation time from 30 min
to 1 h increased the virus expression/replication by approximately 50%, but no further signifi-
cant enhancement of infection was observed after prolonged centrifugation. Therefore, we
Fig 3. DMSO enhances HBV infection in HepG2-NTCP12 cells. Approximately 5×105 HepG2-NTCP12 cells were mock infected or infected with HBV (100
g.e/cell) in the absence or presence of 2% DMSO. DMSOwas added to the PMMmedium 24 h prior to the infection and remained present in the entire
culture period until the cells were harvested. (A) Cells were immunostained with antibodies against HBV capsid protein (HBcAg) and visualized under
fluorescence microscopy. Nuclei were counterstained with DAPI. The image shown represents five different microscopic fields, the percentage of HBcAg-
positive cells was indicated (Mean ± SD) (similarly hereinafter). (B) HBV RNA were extracted from the infected cells and analyzed by Northern blot
hybridization by using an [α-32P] UTP-labeled plus-strand-specific full-length HBV riboprobe. HBV 3.5 kb precore/pregenomic RNA and the 2.4/ 2.1 kb
subgenomic RNA are labeled. Cellular 28S and 18S ribosomal RNA served as loading control. C9-tagged NTCP expression was detected byWestern blot
with β-actin serving as loading control.
doi:10.1371/journal.pone.0129889.g003
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Fig 4. HBV infection of HepG2-NTCP12 cells with different viral inoculum size. Cells were mock infected
or infected with HBV at indicated inoculum size (vge/cell) in the presence of 2% DMSO. Seven days later, the
cells were subjected to HBcAg immunofluorescence microscopy (A). The intracellular HBV RNA and core
DNA were analyzed by Northern and Southern blot, respectively (B).
doi:10.1371/journal.pone.0129889.g004
HBV Spinoculation
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finalized the HBV spinoculation condition to the following key parameters: 500 vge/cell,
1,000g, and 60 min. Under this optimized spinoculation condition, HBV cccDNA and depro-
teinized (protein-free) RC DNA produced in a 35-mm-dish of infected HepG2-NTCP12 cells
at day 8 post infection were detected by conventional Southern blot, and the authenticity of
cccDNA was validated by heat denaturing and additional EcoRI linearization according to our
previously published method [25] (Fig 6C). However, HBV infection under the same above
condition but without centrifugation did not produce detectable level of cccDNA by Southern
blot (data not shown). The detection of cccDNA and its transcripts in the spinoculated cells
clearly demonstrates that the observed HBcAg and core DNA in this system is due to infection
of the cells and viral replication, and not from the detection of the HBV inoculum.
Interestingly, in contrast to HBV stable cell lines, in which the deproteinized (dp) RC DNA
is an overwhelming HBV DNA species in the Hirt extraction [20, 26–28], cccDNA level was
slightly more than dp-RC DNA in the Hirt DNA from HBV infected HepG2-NTCP12 cells
(Fig 6C), indicating that the conversion from dp-RC DNA to cccDNA is more efficient or the
level of RC DNA deproteination is low in the infected HepG2-NTCP12 cells.
Fig 5. Centrifugal inoculation of HBV.HepG2-NTCP12 cells in 24-well-plate were inoculated by HBV (500 vge/cell) without centrifugation or at different
centrifugal force (g) for 30 min. After spinoculation, the cells were transferred to regular culture condition. 7 days later, the infected cells were analyzed by
HBcAg immunofluorescence (A), the levels of intracellular HBV RNA transcription and DNA replication were determined by Northern and Southern blot,
respectively (B).
doi:10.1371/journal.pone.0129889.g005
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Fig 6. Effect of centrifugation time on HBV spinoculation. HepG2-NTCP12 cells were inoculated with
HBV (500 vge/cell) by centrifugation at 1,000×g for different time as indicated. 8 days post inoculation, HBV
infection was analyzed by HBcAg immunofluorescence (A), viral RNA and core DNA hybridization (B), and
HBV cccDNA produced by 60-min-spinoculation was detected by Southern blot and validated by heat
denature and EcoR I linearization (C).
doi:10.1371/journal.pone.0129889.g006
HBV Spinoculation
PLOS ONE | DOI:10.1371/journal.pone.0129889 June 12, 2015 10 / 16
Dependence of NTCP in HBV entry during spinoculation
In order to rule out a possibility that the spinoculation-mediated HBV infection might bypass
the receptor NTCP and take an alternative way to invade the cells, we performed HBV spino-
culation with the parental NTCP-null HepG2 cells and the HepG2-NTCP12 cells in the ab-
sence or presence of HBV entry inhibitors. As shown in Fig 7, HepG2 cells were not susceptible
to HBV spinoculation (top panel); in HepG2-NTCP12 cells, spinoculation-mediated HBV in-
fection was dramatically inhibited by HBV entry inhibitors that block the binding of HBV viri-
on to NTCP, such as Myrcludex B (Myr-B) [9], sodium taurocholate [29], and cyclosporin A
(CsA) [30, 31]. Collectively, the data suggest that spinoculation-mediated HBV infection re-
quires virus receptor NTCP and spinoculation does not replace the authentic HBV entry route.
Discussion
The human NTCP-complementing hepatocyte-derived cell provides a valuable tool for study-
ing HBV infection in vitro. However, similarly to PHH and HepaRG cells, the application of
this infectious system is hampered by its limited susceptibility and reliability [32, 33]. The pos-
sible explanations for the inefficient HBV infection in NTCP-reconstituted HepG2 or Huh7
cells may include, but not limited to, 1) the low infectivity of HBV inoculum. Currently, the
commonly used HBV inoculum is prepared from culture supernatant of HBV producing cell
lines due to their convenient accessibility. In most studies, hundreds to thousands of vge per
cell were needed to inoculate the cells (Fig 4) [7, 9, 10], which indicated that the percentage of
infectious virions in the cell culture-derived virus particles is low. It is thus worthwhile to
screen clinical HBV-positive blood samples for highly infectious seeds to be used in cell culture
experiments; 2) the potential inhibitory effect of subviral particles in HBV inoculum. The non-
infectious HBV subviral particles, also known as HBsAg, contain all the three HBV envelope
proteins (L/M/S) and coexist in great excess relative to the infectious virions, which may com-
pete the binding of HBV virion to receptor(s) on the cell surface [34]; 3) the low permissiveness
of recipient cells to HBV infection. To confer the susceptibility of non-permissive human he-
patic cells to HBV infection, the reconstitution of NTCP is definitely a key requirement, but ad-
ditional factors may also be required to support the internalization and post entry events, such
as cccDNA formation and transcription. In this regard, an optimal culture condition that
maintains the hepatocyte-specific cellular environment and functions is thus needed.
In order to optimize the robustness of the current HBV in vitro infection system comple-
mented with NTCP, we developed a spinoculation method that markedly enhanced HBV in-
fection in NTCP-expressing HepG2-NTCP12 cells compared to the regular inoculation
method. Importantly, centrifugal enhancement of HBV infection remains NTCP-dependent,
suggesting the authentic NTCP-mediated virus entry is boosted by spinoculation. In addition,
centrifugal inoculation is easy to implement without sophisticated manipulations. To rule out a
possibility that the enhancement of HBV infectivity by spinoculation is limited to this particu-
lar HepG2-NTCP12 cell line, we tested spinoculation protocol in another HepG2/NTCP cell
line established recently by Seeger et al [8], and found that the HBV infection efficiency in
HepG2/NTCP cells was markedly enhanced by spinoculation as well (data not shown). There-
fore, spinoculation could serve as a standard procedure in the protocol for HBV infection in
human hepatocyte-derived cells (HepG2 and Huh7) complemented with NTCP, and most
likely in PHH and HepaRG cells as well.
Spinoculation has been used to enhance the infection of a variety of viruses, such as human
and murine cytomegaloviruses [35, 36], herpes simplex virus (HSV) [37], bluetongue virus
[38], adenoviruses [39], influenza A virus [40], hepatitis C virus [41], and retroviruses includ-
ing HIV-1 [14, 15, 36, 42, 43]. However, the spin-mediated enhancement of virus infection is
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not universal, the exceptions include pseudorabies virus and Sindbis virus [13, 35]. Having
been used for more than 50 years, the underlying mechanisms of spin-mediated augment of
virus infection remain elusive. It is generally acknowledged that there is a simultaneous re-
quirement for the presence of both viruses and cells during spinoculation, and the effects on
both counterparts by centrifugation contribute to the enhanced infection [14, 41]. First, al-
though the low speed (normally 100×g to 2,000×g) used in centrifugal inoculation is not pow-
erful enough to spin down the virus particles, some studies suggested that the centrifugation
may generate a concentrating effect to facilitate the contact of viruses with cell surface, remov-
ing certain rate-limiting step(s) and increasing the binding of virus to its receptor(s) [15, 42].
Such effect may be more profound in HBV spinoculation as the inoculation medium contains
4% PEG. It has been reported that HSV spinoculation bypassed the requirement of coreceptor
Fig 7. Spinoculation-mediated HBV infection is NTCP-dependent.HepG2 and HepG2-NTCP12 cells were spinoculated with HBV (500 vge/cell,
1,000×g, 60 min) in the absence or presence of indicated compounds. 8 days post inoculation, the infected cells were analyzed by
HBcAg immunofluorescence.
doi:10.1371/journal.pone.0129889.g007
HBV Spinoculation
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heparan sulfate proteoglycans (HSPGs) [44], and HBV infection of HepaRG cells also utilizes
hepatocyte-associated HSPGs as low affinity attachment receptors [45]. In this study, we found
that HBV receptor NTCP is indispensable in spin-mediated HBV infection (Fig 7), it is there-
fore of interest to investigate whether spinoculation enhances the initial binding of HBV to
HSPGs on cell surface or even replaces the requirement for HSPGs.
On the other hand, the centrifugal stress during spinoculation may also influence the cellu-
lar biophysical and/or biochemical behaviors, making the cells more permissive for virus infec-
tion and replication. In this regard, the mechanistic study of spinoculation-mediated HIV-1
infection revealed that centrifugation activates cofilin and subsequently triggers the dynamics
of cortical actin in CD4 T cells, by which softens a major cytoskeletal barrier for HIV-1 entry
and leads to a series of beneficial activities that enhance HIV-1 receptor mobilization and bind-
ing, virus entry, reverse transcription, and nuclear migration [14]. The potential centrifugal ef-
fect on actin dynamics in hepatocytes and the role of actin network in HBV and HCV infection
await further investigation. However, while membrane fusion-mediated HIV-1 entry is re-
stricted by cortical actin, it may not be a key limiting factor for HBV and HCV which infect the
hepatocytes through endocytosis [46, 47]. Additionally, whether the observed enhancement of
HBV infection by spinoculation is partially due to the centrifugation-mediated stimulation of
HBV cccDNA formation/transcription and/or DNA replication remains unclear. It is also wor-
thy of note that, comparing to the reported double-digit to three-figure fold enhancement of
virus infection by spinoculation, the centrifugal promotion on HBV infection is only several-
fold, which is similar to HCV spinoculation [41]. While there still might be a room for further
optimization of HBV spinoculation, it is also possible that the hepatocytes are inherently some-
what refractory to spin-mediated enhancement of virus infection.
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